Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
May 24, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that Perrigo Chairman, President and Chief Executive Officer, Joseph C. Papa, will present at the...
-
May 22, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated...
-
May 18, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated...
-
May 15, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that Perrigo Executive Vice President and Chief Financial Officer, Judy L. Brown, will present at...
-
May 8, 2012-- Fiscal third quarter revenue from continuing operations increased $86 million, or 13%, to $778 million
Perrigo Company (Nasdaq: PRGO; TASE) today announced results for its third quarter ended March 31, 2012. (Logo:...
-
May 3, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that its Board of Directors declared a quarterly dividend of $0.08 per share, payable on June 19,...
-
Apr 24, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that it will release financial results for its third quarter fiscal 2012 on Tuesday, May 8, 2012...
-
Apr 12, 2012
Perrigo Company (Nasdaq: PRGO; TASE) announced that it has initiated shipments of its Guaifenesin Extended-Release Tablets, 600mg (a generic version...
-
Mar 21, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received a final "Approval for Registration" letter from the Australian Therapeutic...
-
Mar 13, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that its Chairman, President and CEO Joseph C. Papa will present at the Barlcays Capital Global...
-
Mar 1, 2012
Perrigo Company (Nasdaq: PRGO; TASE) announced that it has initiated market launch and made its first shipments of minoxidil 5% foam to its retail and...
-
Feb 28, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced its Chairman & CEO Joseph Papa will present at the RBC Capital Markets' Healthcare Conference on...
-
Feb 14, 2012
Perrigo Company (Nasdaq: PRGO; TASE) announced that it has begun shipping Loratadine-D 12 hour extended release tablets, the store brand equivalent to...
-
Feb 8, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that Perrigo CFO Judy Brown will present at the Leerink Swann 2012 Global Healthcare Conference on...
-
Feb 7, 2012- Fiscal second quarter revenue from continuing operations increased $121 million, or 17%, to a record $838 million
Perrigo Company (Nasdaq: PRGO; TASE) today announced results for its second quarter and six months ended December 31, 2011. Perrigo's Chairman and CEO...
-
Feb 2, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that its Board of Directors declared a quarterly dividend of $0.08 per share, payable on March 20,...
-
Jan 24, 2012
Perrigo Company (Nasdaq: PRGO;TASE: PRGO) today announced that it will release financial results for its second quarter fiscal 2012 on Tuesday,...
-
Jan 23, 2012
Perrigo Company (Nasdaq: PRGO;TASE) announced that it has filed with the U.S. Food and Drug Administration (FDA) an Abbreviated New Drug Application...
-
Jan 12, 2012
Perrigo Company (NASDAQ: PRGO; TASE) announced today that the United States District Court for the Western District of Michigan has granted summary...
-
Jan 9, 2012- CanAm Care expands Perrigo's diabetes care product offering
Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has signed a definitive agreement to acquire substantially all of the assets of CanAm...
-
Jan 6, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the 30th Annual J.P. Morgan Healthcare...
-
Dec 27, 2011
Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated...
-
Nov 28, 2011
Perrigo Company (Nasdaq: PRGO; TASE) today announced that it received final approval from the U.S. Food and Drug Administration (FDA) for its...
-
Nov 15, 2011
Perrigo Company (NASDAQ: PRGO; TASE) today announced it received Food and Drug Administration (FDA) clearance to market and distribute infant formula...
-
Nov 8, 2011
Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has entered into Cooperation and License agreements with Brilite Nutritionals (Shanghai)...